ATE361913T1 - Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren - Google Patents

Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren

Info

Publication number
ATE361913T1
ATE361913T1 AT01966367T AT01966367T ATE361913T1 AT E361913 T1 ATE361913 T1 AT E361913T1 AT 01966367 T AT01966367 T AT 01966367T AT 01966367 T AT01966367 T AT 01966367T AT E361913 T1 ATE361913 T1 AT E361913T1
Authority
AT
Austria
Prior art keywords
protease inhibitors
intermediate products
retroviral protease
producing retroviral
amino
Prior art date
Application number
AT01966367T
Other languages
English (en)
Inventor
Sanjay Chemburkar
Ketan Patel
Harry Spiwek
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24614772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361913(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE361913T1 publication Critical patent/ATE361913T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT01966367T 2000-08-31 2001-08-29 Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren ATE361913T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65191900A 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
ATE361913T1 true ATE361913T1 (de) 2007-06-15

Family

ID=24614772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966367T ATE361913T1 (de) 2000-08-31 2001-08-29 Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren

Country Status (16)

Country Link
EP (1) EP1313712B1 (de)
JP (1) JP5021141B2 (de)
KR (1) KR100806533B1 (de)
CN (1) CN1264823C (de)
AT (1) ATE361913T1 (de)
AU (1) AU2001286889A1 (de)
BR (1) BR0108146A (de)
CA (2) CA2731273C (de)
CY (1) CY1106738T1 (de)
DE (1) DE60128367T2 (de)
DK (1) DK1313712T3 (de)
ES (1) ES2284684T3 (de)
IL (1) IL153436A0 (de)
MX (1) MXPA03001751A (de)
PT (1) PT1313712E (de)
WO (1) WO2002018349A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378669T3 (es) * 2003-12-11 2012-04-16 Abbott Laboratories Compuestos inhibidores de proteasa de VIH
CN100358521C (zh) * 2004-12-28 2008-01-02 哈尔滨欧替药业股份有限公司 一种双唑泰栓剂及其制备工艺
CN103910634B (zh) * 2012-12-29 2018-04-27 广东东阳光药业有限公司 西格列汀中间体的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
CA2731273A1 (en) 2002-03-07
CA2731273C (en) 2013-10-15
PT1313712E (pt) 2007-07-25
CA2416955C (en) 2011-04-26
EP1313712B1 (de) 2007-05-09
KR20030061787A (ko) 2003-07-22
WO2002018349A2 (en) 2002-03-07
JP5021141B2 (ja) 2012-09-05
ES2284684T3 (es) 2007-11-16
CY1106738T1 (el) 2012-05-23
IL153436A0 (en) 2003-07-06
AU2001286889A1 (en) 2002-03-13
DK1313712T3 (da) 2007-09-10
CA2416955A1 (en) 2002-03-07
WO2002018349A3 (en) 2002-05-10
HK1057040A1 (en) 2004-03-12
JP2004507528A (ja) 2004-03-11
MXPA03001751A (es) 2003-09-10
CN1449388A (zh) 2003-10-15
CN1264823C (zh) 2006-07-19
EP1313712A2 (de) 2003-05-28
DE60128367T2 (de) 2008-01-10
KR100806533B1 (ko) 2008-02-25
DE60128367D1 (de) 2007-06-21
BR0108146A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
EP1594889A4 (de) Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
BR0215405A (pt) Composições e processos de uso de collajolie
DK0920410T3 (da) Fremgangsmåde til fremstilling af cyclohexencarboxylatderivater
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
EA199800844A1 (ru) Способ получения r-альфа-пропил-пиперониламина и его аналогов, промежуточные продукты, используемые в этом способе
PT1060175E (pt) Inibidores de triptase
ATE204851T1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
ATE433458T1 (de) Modulatoren von ship-1
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE270275T1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE361913T1 (de) Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren
DE60309847D1 (de) Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
DE50309260D1 (de) Verfahren zur herstellung von bicalutamid
ATE242772T1 (de) Verfahren zur herstellung von hiv-protease inhibitoren
DE60325390D1 (de) Verfahren zur herstellung von zwischenprodukten
SE9800865D0 (sv) New Process
ATE327987T1 (de) Methylthiophencarboxanilide
DE10295581D2 (de) Verfahren zur Synthese von All-D-Peptiden
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
DE59808476D1 (de) VERFAHREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ENTHALTEND HMG-CoA- REDUKTASEINHIBITOREN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313712

Country of ref document: EP